This week we launch a in The Lancet, which aims to provide up-to-date evidence-based reviews for clinicians on new and up-and-coming therapeutic options for diseases. The primary focus will be on new drugs in a specific disease, but broad-based reviews on a drug class or on new non-pharmacological options will also be included. The first Therapeutics paper on faecal microbiota transplantation is an excellent example of emerging therapeutic indications for restoration of the gut microbiota and reviews the treatment of recurrent Clostridioides difficile infection and potential other clinical uses.

中文翻译：

---

柳叶刀疗法

本周，我们将在《柳叶刀》杂志上启动，旨在为临床医生提供最新的，循证的，有关疾病治疗新方法和新方法的评论。主要侧重于特定疾病的新药，但也将包括对药物类别或新的非药理学选择的广泛评论。关于粪便微生物群移植的第一篇治疗论文是恢复肠道微生物群的新兴治疗指征的一个很好的例子，并回顾了难治性梭状芽胞杆菌复发性感染的治疗方法和潜在的其他临床用途。